A citation-based method for searching scientific literature

Qiming Tan, Seun E Akindehin, Camila E Orsso, Richelle C Waldner, Richard D DiMarchi, Timo D Müller, Andrea M Haqq. Front Endocrinol (Lausanne) 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100


Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetologia 2018
594
100

Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.
L Zanoli, A Granata, P Lentini, S Rastelli, P Fatuzzo, F Rapisarda, P Castellino. ScientificWorldJournal 2015
23
100


Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling.
Muthiah Vaduganathan, Vasanth Sathiyakumar, Avinainder Singh, Cian P McCarthy, Arman Qamar, James L Januzzi, Benjamin M Scirica, Javed Butler, Christopher P Cannon, Deepak L Bhatt. J Am Coll Cardiol 2018
68
100



Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.
David M Williams, Hannah Jones, Jeffrey W Stephens. Diabetes Metab Syndr Obes 2022
6
100

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
315
100

Mortality attributable to type 2 diabetes mellitus in Latin America and the Caribbean: a comparative risk assessment analysis.
Wilmer Cristobal Guzman-Vilca, Rodrigo M Carrillo-Larco. BMJ Open Diabetes Res Care 2022
1
100



Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.
C D Sjöström, M Hashemi, J Sugg, A Ptaszynska, E Johnsson. Diabetes Obes Metab 2015
33
100

Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results.
Sean Kang, Subodh Verma, Ali Fatehi Hassanabad, Guoqi Teng, Darrell D Belke, Jameson A Dundas, David G Guzzardi, Daniyil A Svystonyuk, Simranjit S Pattar, Daniel S J Park,[...]. Can J Cardiol 2020
50
100

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
214
100


An update on the safety of SGLT2 inhibitors.
André J Scheen. Expert Opin Drug Saf 2019
66
100

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review.
Soghra Rabizadeh, Manouchehr Nakhjavani, Alireza Esteghamati. Int J Endocrinol Metab 2019
21
100

Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
A Solini, G Sebastiani, L Nigi, E Santini, C Rossi, F Dotta. Diabetes Metab 2017
40
100

Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes.
Yun Kyung Cho, Jiwoo Lee, Yu Mi Kang, Jee Hee Yoo, Joong-Yeol Park, Chang Hee Jung, Woo Je Lee. PLoS One 2019
4
100

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Shang-Hung Chang, Ming-Jui Hung, Yuk-Ying Chan, Edward Chia-Cheng Lai. Cardiovasc Diabetol 2021
4
100


Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Tamara Y Milder, Sophie L Stocker, Christina Abdel Shaheed, Lucy McGrath-Cadell, Dorit Samocha-Bonet, Jerry R Greenfield, Richard O Day. J Clin Med 2019
23
100


Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities.
Abhinav Kanwal, Navjot Kanwar, Sanjay Bharati, Prateek Srivastava, Shailendra P Singh, Salomon Amar. Biomedicines 2022
1
100

SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review.
Daria M Keller, Natasha Ahmed, Hamza Tariq, Malsha Walgamage, Thilini Walgamage, Azad Mohammed, Jadzia Tin-Tsen Chou, Marta Kałużna-Oleksy, Maciej Lesiak, Ewa Straburzyńska-Migaj. J Clin Med 2022
1
100

Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
Emily Brown, John P H Wilding, Thomas M Barber, Uazman Alam, Daniel J Cuthbertson. Obes Rev 2019
56
100

Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study.
Jakob S Knudsen, Signe S Knudsen, Adam Hulman, Daniel R Witte, Edward W Gregg, Torsten Lauritzen, Lars Pedersen, Henrik T Sørensen, Reimar W Thomsen. Lancet Reg Health Eur 2022
1
100


Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Arnaud D Kaze, Min Zhuo, Seoyoung C Kim, Elisabetta Patorno, Julie M Paik. Cardiovasc Diabetol 2022
1
100

Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Raffaella Vero, Francesco Saverio Brunetti, Domenica Maria Corigliano, Biagio Arcidiacono, Daniela Patrizia Foti, Luigi Puccio, Antonio Brunetti. J Diabetes Res 2019
22
100

Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019.
Saeid Safiri, Nahid Karamzad, Jay S Kaufman, Arielle Wilder Bell, Seyed Aria Nejadghaderi, Mark J M Sullman, Maziar Moradi-Lakeh, Gary Collins, Ali-Asghar Kolahi. Front Endocrinol (Lausanne) 2022
3
100

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
100

Harms and benefits of sodium-glucose co-transporter 2 inhibitors.
Thomas Chesterman, Tilenka Rj Thynne. Aust Prescr 2020
2
100

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
W Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J Davies. Metabolism 2018
108
100

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.
Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, David Z I Cherney. Kidney Int Rep 2022
1
100





Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.
Siddhartha Dutta, Tarun Kumar, Surjit Singh, Sneha Ambwani, Jaykaran Charan, Shoban B Varthya. J Family Med Prim Care 2022
1
100


Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Faiez Zannad. JAMA Cardiol 2017
210
100

An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.
Daniel S Hsia, Owen Grove, William T Cefalu. Curr Opin Endocrinol Diabetes Obes 2017
131
100

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Shiho Komatsu, Takashi Nomiyama, Tomohiro Numata, Takako Kawanami, Yuriko Hamaguchi, Chikayo Iwaya, Tsuyoshi Horikawa, Yuki Fujimura-Tanaka, Nobuya Hamanoue, Ryoko Motonaga,[...]. Endocr J 2020
16
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.